Analysts Set Carisma Therapeutics, Inc. (NASDAQ:CARM) Price Target at $4.94

Carisma Therapeutics, Inc. (NASDAQ:CARM) has been given an average recommendation of “Hold” by the seven analysts that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $4.94.

A number of equities research analysts have issued reports on CARM shares. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. D. Boral Capital lowered their price target on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, December 9th. Evercore ISI reiterated an “in-line” rating and issued a $0.70 price objective (down from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th. Finally, Baird R W downgraded Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th.

Institutional Investors Weigh In On Carisma Therapeutics

Several hedge funds have recently made changes to their positions in the company. Barclays PLC raised its holdings in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Carisma Therapeutics in the 2nd quarter worth about $40,000. Finally, Wexford Capital LP lifted its position in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after acquiring an additional 15,000 shares during the period. 44.27% of the stock is currently owned by institutional investors.

Carisma Therapeutics Stock Down 0.6 %

CARM opened at $0.47 on Monday. The company has a market cap of $19.67 million, a P/E ratio of -0.30 and a beta of 1.44. Carisma Therapeutics has a 12 month low of $0.38 and a 12 month high of $2.94. The business’s 50-day moving average price is $0.69 and its 200-day moving average price is $0.93. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The firm had revenue of $3.39 million during the quarter. On average, equities analysts expect that Carisma Therapeutics will post -1.32 EPS for the current year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.